keyword
MENU ▼
Read by QxMD icon Read
search

Blood group incompatibility

keyword
https://www.readbyqxmd.com/read/29783824/-clinical-analysis-of-seven-cases-of-rare-hemolytic-disease-of-the-newborn
#1
S Gu, H X Wang, C Y Yang, X F Yang, Y Lin, Y Zhong, J P He, Y J Wang
Objective: To summarize the clinical features of 7 rare cases of hemolytic disease of newborn (HDN), and to improve the understanding of rare HDN. Methods: Data of clinical information, laboratory findings, treatments and outcomes were collected and analyzed for four cases with HDN due to anti-M, two cases due to anti-Kidd, and one case due to anti-Duffy. All of them were admitted to the Department of Neonatology, Beijing Children's Hospital Affiliated to Capital Medial University from July 2007 to June 2017...
May 2, 2018: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/29731065/vdj-gene-usage-of-b-cell-receptors-in-peripheral-blood-of-abo-incompatible-kidney-transplantation-patients
#2
H J Jeon, T Fang, J-G Lee, J Y Jang, K Kim, S Choi, J-J Yan, J H Ryu, T Y Koo, C Ahn, J Yang
INTRODUCTION: B cell subtypes and immunoglobulin variable (V), diversity (D), joining (J) gene segment usage of B cell receptors in ABO-incompatible (ABOi) kidney transplantation (KT) in comparison to ABO-compatible KT have not been studied. The aims of this study were to analyze the VDJ gene segment usages of B cell receptors in peripheral blood of ABOi KT recipients. METHODS: Eighteen ABOi KT patients with accommodation (ABOiA), 10 ABO-compatible stable KT patients (ABOcS), and 10 ABOi KT patients with biopsy-proven acute antibody-mediated rejection (ABOiR) at day 10 after transplantation were selected...
May 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29724631/transfusion-policy-in-allogeneic-hematopoietic-stem-cell-transplantation
#3
REVIEW
Pervin Topcuoglu
The incompatibility of ABO blood group between the recipient and the donor is not a barrier to perform allogeneic hematopoietic stem cell transplantation (Allo-HSCT). However, ABO incompatibility may lead to many complications during and after stem cell transplantation at the early or late period. Therefore, the typing of the blood group of the recipient and the donor should be done prior to the transplantation. In addition, the ABO/Rh group of blood products for transfusion should be determined according to the type of ABO-incompatibility...
April 18, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29700043/enhancement-of-red-blood-cell-transfusion-compatibility-using-crispr-mediated-erythroblast-gene-editing
#4
Joseph Hawksworth, Timothy J Satchwell, Marjolein Meinders, Deborah E Daniels, Fiona Regan, Nicole M Thornton, Marieangela C Wilson, Johannes Gg Dobbe, Geert J Streekstra, Kongtana Trakarnsanga, Kate J Heesom, David J Anstee, Jan Frayne, Ashley M Toye
Regular blood transfusion is the cornerstone of care for patients with red blood cell (RBC) disorders such as thalassaemia or sickle-cell disease. With repeated transfusion, alloimmunisation often occurs due to incompatibility at the level of minor blood group antigens. We use CRISPR-mediated genome editing of an immortalised human erythroblast cell line (BEL-A) to generate multiple enucleation competent cell lines deficient in individual blood groups. Edits are combined to generate a single cell line deficient in multiple antigens responsible for the most common transfusion incompatibilities: ABO (Bombay phenotype), Rh (Rhnull ), Kell ( K 0 ), Duffy (Duffynull ), GPB (S- s- U- )...
April 26, 2018: EMBO Molecular Medicine
https://www.readbyqxmd.com/read/29687886/false-negative-compatible-antiglobulin-crossmatches-in-samples-with-alloantibodies-to-cognate-red-blood-cell-antigens
#5
Christian P Nixon, Stephanie L Krohto, Joseph D Sweeney
BACKGROUND: Patient samples showing a positive indirect antiglobulin test are further tested to identify alloantibody specificity using a panel of phenotypically characterized group O reagent red blood cells (RBCs). Donor RBCs phenotypically negative for the antibody specificity are then serologically crossmatched using an antiglobulin reagent. This latter test is performed to identify any incompatibility due to the presence of undetected minor blood group antibodies and considered an important step in patient safety...
April 24, 2018: Transfusion
https://www.readbyqxmd.com/read/29686715/knowledge-level-and-determinants-of-neonatal-jaundice-a-cross-sectional-study-in-the-effutu-municipality-of-ghana
#6
Prince Adoba, Richard K D Ephraim, Kate Adomakowaah Kontor, Joseph-Josiah Bentsil, Patrick Adu, Maxwell Anderson, Samuel Asamoah Sakyi, Paul Nsiah
Background: Neonatal jaundice (NNJ) is a major cause of hospital admission during the neonatal period and is associated with significant mortality. This case-control study with cross-sectional design sought to identify the possible factors associated with neonatal jaundice and assess maternal knowledge level of this condition. Methods: One hundred and fifty (150) neonates comprising 100 with clinically evident jaundice and 50 without jaundice were conveniently recruited from the Trauma and Specialist Hospital in the Effutu Municipality...
2018: International Journal of Pediatrics
https://www.readbyqxmd.com/read/29616895/ceftriaxone-resistant-salmonella-typhi-carries-an-inci1-st31-plasmid-encoding-ctx-m-15
#7
Bilal Djeghout, Senjuti Saha, Mohammad Saiful Islam Sajib, Arif Mohammad Tanmoy, Maksuda Islam, Gemma L Kay, Gemma C Langridge, Hubert P Endtz, John Wain, Samir K Saha
PURPOSE: Ceftriaxone is the drug of choice for typhoid fever and the emergence of resistant Salmonella Typhi raises major concerns for treatment. There are an increasing number of sporadic reports of ceftriaxone-resistant S. Typhi and limiting the risk of treatment failure in the patient and outbreaks in the community must be prioritized. This study describes the use of whole genome sequencing to guide outbreak identification and case management. METHODOLOGY: An isolate of ceftriaxone-resistant S...
April 4, 2018: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/29608324/the-devil-is-in-the-details-retention-of-recipient-group-a-type-5-years-after-a-successful-allogeneic-bone-marrow-transplant-from-a-group-o-donor
#8
Laura L W Cooling, Michelle Herrst, Sherri L Hugan
ABO-incompatible (ABOi) hematopoietic stem cell transplants (HSCTs) can present challenges in the blood bank. During transplantation, patients receive components that are ABO-compatible with both the donor graft and recipient; this practice can strain group O red blood cell (RBC) inventories.1 In addition, there are risks for acute hemolysis at the time of infusion and in the early post-transplant period.1,2 In ABO major-incompatible bone marrow HSCTs, which contain significant quantities of donor RBCs that are ABOi with recipient plasma, it is common to perform a RBC depletion of the bone marrow in an effort to minimize hemolysis at the time of infusion...
January 2018: Immunohematology
https://www.readbyqxmd.com/read/29563676/an-approach-to-incompatible-cross-matched-red-cells-our-experience-in-a-major-regional-blood-transfusion-center-at-kolkata-eastern-india
#9
Prasun Bhattacharya, Eeshita Samanta, Nowroz Afroza, Archana Naik, Rathindranath Biswas
INTRODUCTION: With the increased utilization of immunohematology (IH) analyzers in the transfusion medicine, type, and screen policy is the method of choice. Still, the importance of routine crossmatching could not be overruled. Here, we tried to understand the clinical conditions and safety of red cell transfusion and their outcomes. MATERIALS AND METHODS: This prospective study was conducted by IH laboratory, Medical College Kolkata, Blood Bank from October 1, 2015 to March 31, 2016...
January 2018: Asian Journal of Transfusion Science
https://www.readbyqxmd.com/read/29509285/impact-of-the-new-kidney-allocation-system-a2-a2b-%C3%A2-b-policy-on-access-to-transplantation-among-minority-candidates
#10
Paulo N Martins, Margaux N Mustian, Paul A MacLennan, Jorge A Ortiz, Mohamed Akoad, Juan Carlos Caicedo, Gabriel J Echeverri, Stephen H Gray, Reynold I Lopez-Soler, Ganesh Gunasekaran, Beau Kelly, Constance M Mobley, Sylvester M Black, Carlos Esquivel, Jayme E Locke
Blood group B candidates, many of whom represent ethnic minorities, have historically had diminished access to deceased donor kidney transplantation (DDKT). The new national kidney allocation system (KAS) preferentially allocates blood group A2/A2B deceased donor kidneys to B recipients to address this ethnic and blood group disparity. No study has yet examined the impact of KAS on A2 incompatible (A2i) DDKT for blood group B recipients overall or among minorities. A case-control study of adult blood group B DDKT recipients from 2013 to 2017 was performed, as reported to the Scientific Registry of Transplant Recipients...
March 6, 2018: American Journal of Transplantation
https://www.readbyqxmd.com/read/29499077/human-leukocyte-antigen-compatibility-and-lymphocyte-cross-matching-play-no-significant-role-in-the-current-adult-to-adult-living-donor-liver-transplantation
#11
Amr Badawy, Toshimi Kaido, Atsushi Yoshizawa, Shintaro Yagi, Ken Fukumitsu, Hideaki Okajima, Shinji Uemoto
BACKGROUND: The impact of human leukocyte antigen (HLA) compatibility and positive lymphocyte cross-match (LCM) on organ transplantation is well-recognized particularly in kidney and heart transplantation; however, it is still debatable in liver transplantation (LT). So, the aim of this study was to evaluate the impact of HLA mismatch and positive LCM on the outcome of LT. METHODS: We retrospectively analyzed the data of all adult recipients who underwent living donor LT at our institute between January 2010 and July 2016...
April 2018: Clinical Transplantation
https://www.readbyqxmd.com/read/29452208/outcome-of-abo-incompatible-adult-living-donor-liver-transplantation-for-patients-with-hepatocellular-carcinoma
#12
Young-In Yoon, Gi-Won Song, Sung-Gyu Lee, Shin Hwang, Ki-Hun Kim, Seok-Hwan Kim, Woo-Hyoung Kang, Hwui-Dong Cho, Eun-Kyoung Jwa, Jae-Hyun Kwon, Eun-Young Tak, Varvara A Kirchner
BACKGROUND & AIMS: Living-donor liver transplantation (LDLT) can simultaneously cure hepatocellular carcinoma (HCC) and underlying liver cirrhosis, improving long-term results in patients with HCC. ABO-incompatible LDLT could expand the living-donor pool, reduce waiting times for deceased-donor liver transplantation, and improve long-term survival for some patients with HCC. METHODS: We retrospectively reviewed the medical records of patients undergoing LDLT for HCC from November 2008 to December 2015 at a single institution in Korea...
February 13, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29407333/eculizumab-for-prevention-of-antibody-mediated-rejection-in-blood-group-incompatible-renal-transplantation
#13
P West-Thielke, K Progar, M Campara, N Jasiak, L Gallon, I Tang, M Spaggiari, I Tzvetanov, E Benedetti
Antibody-mediated rejection (AMR) is one of the leading causes of allograft failure especially in patients undergoing ABO-incompatible (ABOi) renal transplantation. We hypothesized that complement inhibition with eculizumab, a C5 inhibitor, would protect against AMR and maintain graft function in ABOi renal transplant recipients. Four patients undergoing living donor kidney transplant from ABOi donors were treated with a 9-week eculizumab course without therapeutic plasma exchange, intravenous immunoglobulin, or splenectomy...
January 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29407331/safety-and-efficacy-of-induction-therapy-with-thymoglobulin-in-ab0-incompatible-kidney-transplantation
#14
A L Herzog, C Kalogirou, C Wanner, K Lopau
INTRODUCTION: Data suggest an additional role of T cells in antibody-mediated rejections. In 2001 a protocol for AB0-incompatible kidney transplantation based on B-cell-depleting anti-CD20 antibody rituximab, antigen-specific blood group IgG immunoadsorption, intravenous immunoglobulins, and triple immunosuppression was introduced in Europe, which used induction therapy with the use of interleukin-2 receptor antibody (IL2-RA) basiliximab. We used thymoglobulin in AB0-incompatible patients as induction in the face of high immunologic risk...
January 2018: Transplantation Proceedings
https://www.readbyqxmd.com/read/29378149/clinical-and-laboratory-profile-of-anti-m
#15
Debapriya Basu, Sabita Basu, Mahua Reddy, Kaushik Gupta, Mammen Chandy
Anti-M is a frequently detected naturally occurring antibody that has been reported in various clinical settings and also in voluntary donors. We describe here the clinical and laboratory findings of 11 cases with anti-M detected at our center. This report is a retrospective study in which we reviewed our immunohematology laboratory records for cases involving anti-M. Both donor and patient data from a 28-month period (September 2014 to December 2016) were reviewed. During this period, 11 examples of anti-M were detected (8 patients, 1 voluntary whole blood donor, and 1 hematopoietic stem cell donor...
December 2017: Immunohematology
https://www.readbyqxmd.com/read/29369480/retrospective-analysis-of-hdfn-due-to-abo-incompatibility-in-a-single-institution-over-6-years
#16
A Matteocci, A De Rosa, E Buffone, L Pierelli
OBJECTIVES: To study the rate of ABO haemolytic anaemia of fetus and newborn (HDFN) in one institution over 6 years. BACKGROUND: ABO major incompatibility between mothers and their newborns occurs in about 10% of births. So, mothers with an O blood group may form IgG-class antibodies against A and B antigens, which could pass across the placenta and lead to a variable degree of HDFN in the newborn. METHODS: At our institution, we have reviewed data regarding ABO-based HDFN in the last 6 years...
January 25, 2018: Transfusion Medicine
https://www.readbyqxmd.com/read/29332316/how-do-i-implement-a-whole-blood-program-for-massively-bleeding-patients
#17
Mark H Yazer, Andrew P Cap, Philip C Spinella, Louis Alarcon, Darrell J Triulzi
Building on the successful military experience, interest has been rekindled in transfusing whole blood (WB) early in the resuscitation of traumatically injured civilians, often before their ABO group is known. WB efficiently provides treatment for shock and coagulopathy, as well as platelet hemostatic function, to patients losing large volumes of blood. Unlike group O uncrossmatched red blood cells (RBCs), group O WB contains a substantial amount of plasma, which is incompatible with the RBCs of all non-group O recipients...
March 2018: Transfusion
https://www.readbyqxmd.com/read/29327382/retrospective-analysis-of-forward-and-reverse-abo-typing-discrepancies-among-patients-and-blood-donors-in-a-tertiary-care-hospital
#18
R N Makroo, B Kakkar, S Agrawal, M Chowdhry, B Prakash, P Karna
OBJECTIVE: The aim of our study was to determine the incidence and causes of ABO typing discrepancies among patients and blood donors at our centre. BACKGROUND: An accurate interpretation of the ABO blood group of an individual is of utmost importance to ensure patient safety and good transfusion practices. METHODS: A retrospective observational study was carried out in the Department of Transfusion Medicine in our hospital from March 2013 to December 2015...
January 12, 2018: Transfusion Medicine
https://www.readbyqxmd.com/read/29287058/activities-of-the-thor-aabb-working-party
#19
Mark H Yazer, Philip C Spinella
The AABB (formerly the American Association of Blood Banks) is an international authority on transfusion medicine and tissue banking. The Trauma, Hemostasis and Oxygenation Research (THOR) Network is an international multidisciplinary network of civilian and military providers ranging from first responders and medics to critical care physicians, and from basic scientists to clinical trialists. The THOR Network's vision is to improve outcomes from traumatic hemorrhagic shock by optimizing the acute phase of resuscitation...
December 28, 2017: Journal of Trauma and Acute Care Surgery
https://www.readbyqxmd.com/read/29246114/the-influence-of-hk2-blood-group-antigen-on-human-b-cell-activation-for-aboi-kt-conditions
#20
Jingsong Cao, Luogen Liu, Yunsheng Zhang, Jianhua Xiao, Yi Wang
BACKGROUND: It is well known that ABO blood group system incompatible kidney transplantation (ABOi-KT) is an effective strategy for end-stage renal disease. The main barrier for ABOi-KT is how to keep host B cell activation and blood group antibody titer in low levels. Moreover, the mechanism of B cell activation induced by blood group antigen was unclear in ABOi-KT. RESULTS: In this study, HK2 cells were identified to express blood group B antigen when cocultured with lymphocytes of blood group A...
December 16, 2017: BMC Immunology
keyword
keyword
5933
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"